Epithalon (Epitalon / Epithalamin tetrapeptide)

Khavinson's Ala-Glu-Asp-Gly tetrapeptide — claimed telomerase activator and pineal-melatonin restorer. Russian elderly cohort data (266 subjects, Khavinson + Anisimov 2003) reports 1.6–4.1× mortality reduction over 6-12 yr; A-tier in vitro telomerase upregulation is replicated, but every pivotal animal/human study comes from one lab with commercial conflicts and no NIA-ITP / Western academic replication. For Dylan at 20: WATCH-LIST, LOW-MEDIUM confidence. Telomere attrition plateaus in young adulthood, so the population the data is in (60-80yo) doesn't generalize cleanly to him. The "primes receptor sensitivity for MOTS-c / NAD+ / SS-31" framing he heard externally is a community claim, not a published mechanism. Park on watch-list; revisit when Phase 3 longevity protocol is real (post-25/30) or when an independent Western lab replicates the telomerase data with rigor.

Epithalon is the synthetic short-peptide form of Epithalamin, an extract of bovine pineal gland. Epithalamin is the parent polypeptide preparation (mixed peptides + amino acids from pineal tissue, ~the pineal analog of how Cerebrolysin is the cortical analog). Epitalon / Epithalon is the four-amino-acid sequence Khavinson's group identified as the shortest active fragment: Ala-Glu-Asp-Gly (AEDG), MW 390.4 Da, formula C₁₄H₂₂N₄O₉.

The proposed mechanism stack runs across five claimed layers:

1. Telomerase activation (TERT upregulation). The headline claim. Khavinson's group reports that AEDG binds the hTERT promoter at ATTTC motifs and upregulates transcription of telomerase reverse transcriptase. Independent in vitro work (TRAP — Telomeric Repeat Amplification Protocol — assays in HeLa and human fetal lung fibroblasts; 2003 onward; replicated in some Western cell-line studies including a 2025 paper in human cell lines showing telomerase upregulation OR alternative-lengthening-of-telomeres pathway activation depending on cell type) supports activation in cell culture. Reported effect: human fibroblasts cultured with epitalon extended past the Hayflick limit (~44 passages vs ~34 controls); ~33% mean telomere length increase in lymphocytes from elderly donors across 25-88yo cohorts (Khavinson lab). In vitro telomerase activation is the strongest piece of evidence in the file (call it A-tier on its own); the leap from in vitro to "live human telomere maintenance over years" is where the data thins.
2. Epigenetic / chromatin remodeling. AEDG has been shown (Khavinson group, replicated in some Russian work) to bind methylated cytosine residues and to interact with linker histone H1 (subtypes H1.3, H1.6), suggesting direct nuclear access and gene-expression modulation. The "small peptide enters the nucleus and changes transcription" model is the central, scientifically-controversial pillar of the entire Khavinson bioregulator framework — see Controversies.
3. Pineal melatonin restoration. Multiple rat studies (Khavinson + collaborators 2003 onward) show AEDG upregulates AANAT (arylalkylamine N-acetyltransferase, the rate-limiting melatonin-synthesis enzyme) and pCREB in pinealocytes. In a 75-women sublingual study (0.5 mg/d × 20 d), nocturnal melatonin synthesis rose ~1.6× vs placebo, and circadian-clock gene Cry2 expression in leukocytes doubled while Csnk1e fell ~2.1×. This is the strongest human-subjective use case — improved sleep architecture in an aging pineal — though the trial is small, single-source, and not blinded by Western standards.
4. Antioxidant + Nrf2/Keap1 pathway. Animal data shows upregulation of SOD-1, catalase, NQO1, glutathione peroxidase across multiple tissues. Mechanism not fully worked out — could be direct, downstream of melatonin restoration (melatonin is itself a Nrf2 activator), or both.
5. Immune normalization. Reported CD4+/CD8+ rebalancing, IL-2 upregulation, restoration of thymic structure in animal models with thymic involution. The "pineal-thymus axis" framework is an explicit Khavinson lab signature: pineal peptides + thymic peptides as the two halves of immune-aging restoration (this is why the 2003 Khavinson + Morozov 266-subject study tested epithalamin alone vs + thymalin — and the +thymalin combination showed the largest mortality reduction).

Plain English: It tells aging cells (especially pineal and possibly immune cells) to act younger — make more melatonin, run cleaner antioxidant defenses, maintain telomere caps. Whether these signals are real and sustained in living humans over years, vs. short-term in vitro / rodent / single-lab Russian elderly cohort data, is the open question. For a 20yo whose pineal still runs near peak melatonin output and whose telomeres are at their lifetime plateau, the value proposition is much weaker than for a 70yo where multiple of these pathways are demonstrably degraded.